Seres Therapeutics (NASDAQ:MCRB) Issues Quarterly Earnings Results, Misses Expectations By $0.63 EPS

Seres Therapeutics (NASDAQ:MCRB) released its quarterly earnings data on Wednesday. The biotechnology company reported ($1.63) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.63), FiscalAI reports. Seres Therapeutics had a negative net margin of 1,192.94% and a negative return on equity of 114.82%. The business had revenue of $0.59 million for the quarter, compared to the consensus estimate of $6.35 million.

Seres Therapeutics Price Performance

MCRB stock traded down $0.05 during midday trading on Wednesday, hitting $1.91. The company’s stock had a trading volume of 56,330 shares, compared to its average volume of 70,897. The company’s fifty day moving average price is $3.51 and its 200 day moving average price is $7.05. Seres Therapeutics has a twelve month low of $1.68 and a twelve month high of $29.98. The stock has a market capitalization of $19.20 million, a P/E ratio of -0.78 and a beta of 0.44.

Analyst Ratings Changes

Several research firms recently commented on MCRB. Weiss Ratings cut shares of Seres Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 18th. Wall Street Zen upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $17.00.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a biotechnology company focused on developing live biotherapeutic products designed to restore the function of the human microbiome. The company’s platform uses defined communities of microorganisms rather than conventional fecal material to address diseases associated with microbiome disruption.

Seres’ lead product, VOWST (fecal microbiota spores, live-brpk), was approved by the U.S. Food and Drug Administration in 2023 to prevent the recurrence of Clostridioides difficile infection in adults following antibacterial treatment.